Press & media
Press & media
Everything a journalist needs to describe Vanguard Biotech Systems and NextGenAMR accurately, drawn from approved statements. For interviews, materials or clarifications, use the press contact below.
Please note when writing about NextGenAMR
To describe the product accurately, please do NOT present NextGenAMR as any of the following:
- NextGenAMR is not presented as an autonomous diagnostic system; it organises genomic evidence and generates outputs for professional review.
- NextGenAMR does not replace phenotypic antimicrobial susceptibility testing (AST). Genomic outputs must be interpreted together with AST, microbiological context and applicable procedures.
- NextGenAMR does not select treatments and does not generate autonomous therapeutic recommendations. Clinical decisions remain with qualified professionals.
Corporate boilerplate
Vanguard Biotech Systems is a Spanish technology company founded in 2025 and based in Granada, Spain. It develops bioinformatics software infrastructure to turn complex genomic workflows into more controlled, reproducible, traceable and reviewable processes. NextGenAMR is the first product developed by Vanguard Biotech Systems. Juan Manuel Gómez Vargas — Founder & CEO of Vanguard Biotech Systems.
About the company
Vanguard Biotech Systems is a Spanish technology company founded in 2025 and based in Granada, Spain. It develops bioinformatics software infrastructure to turn complex genomic workflows into more controlled, reproducible, traceable and reviewable processes.
About the company →About NextGenAMR
NextGenAMR is the first product developed by Vanguard Biotech Systems. Vanguard Biotech Systems develops NextGenAMR, a bioinformatics software platform that processes supported WGS data from bacterial isolates within its published scope, organises genomic evidence related to antimicrobial resistance, preserves run-level provenance and generates outputs for professional review. NextGenAMR is currently undergoing controlled evaluation and validation. It is not presented as an autonomous diagnostic system, a replacement for phenotypic AST or a tool that selects treatments.
NextGenAMR is a functional platform in controlled preview. Validation is ongoing, and the product is not presented as an autonomous diagnostic or treatment-decision system.
Company facts
- Founded
- Founded in 2025 in Granada, Spain.
- Location
- Granada, Spain
- Founder & CEO
- Juan Manuel Gómez Vargas — Founder & CEO of Vanguard Biotech Systems.
- First product
- NextGenAMR is the first product developed by Vanguard Biotech Systems.
Media assets
Logos, authorised photographs and additional materials are available on request through the press contact. We do not publish brand assets or internal materials without authorisation.
Press contact
Write to us through the contact form and select “Press”. We reply according to the request.